Cheryl Guttman Krader
Anti-PDGF inhibitor development continues despite negative results
Despite the failure of 2 clinical trials involving a combination therapy of platelet-derived growth factor (PDGF) inhibitor and anti-vascular endothelial growth factor (anti-VEGF) therapy, a third phase III study continues.
5-year CATT analysis finds anti-VEGF drugs a long-term AMD therapy
After 5 years of follow-up in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT), the visual acuity gains achieved during the first 2 years of anti-VEGF treatment were not maintained, the choroidal neovascular lesions continued to evolve with evidence of persistent activity in some eyes, and there was increased retinal thinning and geographic atrophy (GA).
Selective techniques revolutionize treatment for retinoblastoma
Advancements in retinoblastoma have occurred in the areas of treatment, genetic testing, and diagnostic imaging.
Endoillumination growth amplifies tissue visualization
Endoillumination for vitreoretinal surgery continues to improve with the introduction of brighter, safer light sources with color filters that may allow opportunities for better tissue visualization.
Access, costs of bevacizumab key factors for DME therapy
The efficacy of intravitreal bevacizumab (Avastin, Genentech) for improving vision in patients with center-involving diabetic macular edema (DME) has been demonstrated in several clinical trials.
Data clearly demonstrates bevacizumab’s inferiority for DME
All three anti-vascular endothelial growth factor (anti-VEGF) agents that are commercially available have demonstrated efficacy for the treatment of diabetic macular edema (DME). However, it is clear from the results of clinical trials that outcomes with bevacizumab are not as good as those obtained using ranibizumab or aflibercept, according to Jean-François Korobelnik, MD.
Urethral lift: 5-year data point to procedure’s durability
Analyses of data from 5 years of prospective follow-up in the pivotal trial supporting regulatory approval of the prostatic urethral lift ([PUL] UroLift System, NeoTract) show that the minimally invasive procedure remains safe and provides rapid and durable benefits for men with symptomatic BPH.
Intrastromal procedure favored for myopic treatment
A review of 800 cases of small incision lenticule extraction for treatment of myopia and myopic astigmatism shows an evolution in surgical indications and technique with consistently positive outcomes.
Developmental dysplasia of the hip
Developmental dysplasia of the hip (DDH) refers to a spectrum of abnormalities that range in severity from mild instability to frank dislocation. The vast majority of clinical and anatomic hip abnormalities identified in early infancy resolve spontaneously. Left untreated, however, a hip that is persistently unstable and anatomically abnormal can lead to functional limitations, pain, and premature degenerative changes.
DARPin molecule prolongs anti-VEGF activity in nAMD
A phase III study program investigating abicipar pegol (Allergan) for the treatment of neovascular age-related macular degeneration (nAMD) is underway based on promising efficacy and safety results in phase II studies.

Poll

View Results